Renal cell carcinoma · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-TSC-CARRIER-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-20 \| pending_clinical_signoff
Diseases	`DIS-RCC`
Sources	`SRC-NCCN-CNS-2025` `SRC-NCCN-KIDNEY-2025`

Notes

STUB — Wave O confirmed-carrier surveillance pathway (TSC / TSC1 / TSC2). Two-Clinical-Co-Lead signoff queued per CHARTER §6.1 dev-mode. Sibling — IND-TSC-CARRIER-INTENSIFIED (aggressive plan_track). DIS-RCC anchor approximation — TSC is a multi-organ syndrome dominated by surveillance of renal AML / SEGA / LAM rather than a primary cancer anchor; DIS-RCC is the closest available; v0.4 cleanup may add DIS-TSC-SPECTRUM or DIS-RENAL-AML.

Used By

Indication

IND-TSC-CARRIER-INTENSIFIED - IND-TSC-CARRIER-INTENSIFIED

Red flag

RF-TSC-CONFIRMED-CARRIER - Confirmed germline pathogenic / likely-pathogenic variant in TSC1 (hamartin) or TSC2 (tub...